Drug intelligence / Profile preview

GB-6002

Development stage: Phase 1
Lead developer: G2GBio
Modality: Small Molecules
Administration: Local Infiltration

Overview

GB-6002 is a proprietary formulation of ropivacaine developed for local infiltration to manage postoperative pain. Ropivacaine is a long-acting amide-type local anesthetic that works by blocking sodium channels in nerve cells, thereby inhibiting the initiation and conduction of nerve impulses responsible for pain sensation. GB-6002 is being evaluated in clinical trials as a single-dose local infiltration for its safety, tolerability, and pharmacokinetic profile compared to active comparators in healthy adults[1][2][3][4][5].

Other names: GB-6002GB6002GB 6002ropivacaine

Targets

NaV alpha (Voltage-gated sodium channel alpha subunit family)

Beyond the preview

Go deeper on GB-6002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GB-6002.

Explore the full profile